In the study by Bandini et al., PD‐L1 expression, high tumour mutational burden (TMB) (>15 mutations/Mb), and mutations in DNA repair genes were associated with pathological response to pembrolizumab.44 The gene discussed is CD274; the disease is neoplasm.